Kevin Sheth

Kevin Sheth, MD


Dr. Kevin Sheth is the founding Chief of the Division of Neurocritical Care & Emergency Neurology at Yale School of Medicine. His interests are in the advancement of therapies for devastating acute neurological syndromes, especially those complicated by brain ischemia, swelling and hemorrhage. He is a nationally recognized clinical and translational scientist and has directed several multicenter studies. In pioneering the development of new strategies to treat brain swelling, his work has changed the fundamental approach to brain injury in the ICU and spurned the creation of new technologies in drug delivery and neuroimaging. His team at Yale has served as a national model for academic critical care neurology units.

He is currently the principal investigator for two NIH neuroscience networks, NeuroNEXT and StrokeNet and three additional RO1/UO1 awards from the NIH. Dr. Sheth has served as PI or co-PI for 8 multicenter clinical trials in stroke, as well as chair for clinical endpoint and data safety monitoring committees for several pivotal studies. He is the winner of the prestigious Robert Siekert Award from the American Heart Association (AHA) and the Derek Denny Brown Award from the American Neurological Association. His research has been funded by the NIH, American Academy of Neurology, AHA, and the US Army. Dr. Sheth is the author of over 190 publications and has served on study sections for the NIH, AHA, FDA and NASA. He is an Associate Editor at Neurology and on the editorial boards for Stroke and Neurosurgery. His work has been showcased in The Washington Post, Wall Street Journal, NPR and CNN.

Finally, Dr. Sheth has formed exciting partnerships with entrepreneurs, pharmaceutical companies, and medical device start-ups to bring forward highly innovative solutions. These efforts have resulted in extensive knowledge of FDA pathways, development of phase I-III drug programs, and implementation of new technology into the clinical workspace. The principal theme of his efforts are towards collaboration and an improved understanding of neurological disease.